Top Page
Sosei Group
(4565)
Sosei Group (4565) vs. iShares MSCI Japan ETF (EWJ)
Sosei Group Business Overview & Revenue Model
Sosei Group Earnings Call Summary
Sosei Group Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 29.61B | 28.84B | 12.77B | 15.57B | 17.71B |
| Gross Profit | 21.42B | 21.22B | 9.66B | 14.64B | 16.78B |
| EBITDA | -3.91B | 105.00M | -5.71B | 3.57B | 2.19B |
| Net Income | -12.53B | -4.84B | -7.19B | 382.00M | 1.02B |
Balance Sheet | |||||
| Total Assets | 134.79B | 151.50B | 157.20B | 99.42B | 96.98B |
| Cash, Cash Equivalents and Short-Term Investments | 20.36B | 36.20B | 49.06B | 66.56B | 60.17B |
| Total Debt | 60.88B | 67.90B | 73.97B | 29.73B | 29.27B |
| Total Liabilities | 73.79B | 82.98B | 90.39B | 41.48B | 39.52B |
| Stockholders Equity | 61.00B | 68.52B | 66.81B | 57.94B | 57.47B |
Cash Flow | |||||
| Free Cash Flow | -3.12B | -8.24B | -6.12B | 9.65B | 6.89B |
| Operating Cash Flow | -2.67B | -7.72B | -5.27B | 9.95B | 7.09B |
| Investing Cash Flow | 5.43B | -4.76B | -63.79B | 1.04B | 278.00M |
| Financing Cash Flow | -16.03B | -6.85B | 48.33B | -4.89B | 11.12B |
Sosei Group Technical Analysis
Sosei Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | ¥27.57B | -61.60 | ― | ― | -5.65% | -469.19% | |
52 Neutral | ¥82.26B | -6.76 | -9.05% | ― | -1.96% | -64.18% | |
52 Neutral | ¥138.24B | -19.18 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥67.52B | -33.85 | ― | ― | -9.04% | 13.09% | |
48 Neutral | ¥169.33B | -44.05 | -636.97% | ― | ― | -12.69% | |
46 Neutral | ¥174.10B | -48.22 | -10.16% | ― | -62.47% | -134.06% |
Sosei Group Corporate Events
Nxera Pharma has proposed changes to its Board of Directors, nominating physician and healthcare policy expert Takeo Morooka as a new external director while announcing the planned retirement of external directors Miwa Seki and Noriaki Nagai. The board reshuffle, subject to shareholder approval at the March 25, 2026 general meeting, is intended to bolster governance and support the company’s medium- to long-term growth strategy as it pursues a stronger position in the global biopharmaceutical industry.
President and CEO Chris Cargill said Morooka’s extensive regulatory and pharmaceutical policy experience, spanning roles in Japan’s health ministry, the WHO and senior industry posts, is expected to provide practical guidance and strengthen oversight of management. The move comes alongside the reappointment of six existing directors, signaling continuity in leadership while adding specialized policy and regulatory expertise that could enhance Nxera’s ability to navigate complex healthcare markets and accelerate value creation for stakeholders.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma reported a year of disciplined execution in 2025, strengthening its commercial base in Japan and APAC as PIVLAZ consolidated its position as standard of care in aneurysmal subarachnoid haemorrhage and delivered 6.8% annual sales growth. QUVIVIQ sales surged more than threefold following its December 2024 launch with Shionogi, supported by approval of an additional Asian manufacturing site to secure supply and improve profitability.
The company advanced its pipeline through partner-led milestones, including Neurocrine’s Phase 3 start for muscarinic agonist NBI-‘568 and positive Phase 1 data for oncology candidate HTL’732, which has moved into Phase 2. Nxera also executed a focused restructuring to prioritize high-value programs and cut costs toward a 2030 profitability target, regained full rights to its Phase 2–ready GPR52 schizophrenia asset for out-licensing, expanded its late-stage portfolio via licensing DMD drug vamorolone for Japan/APAC, and reported positive Phase 3 data for daridorexant in South Korea ahead of a 2026 filing.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma has moved to sharply cut performance-linked remuneration for its top executives following the disclosure of its full-year 2025 financial results. The company said the decision underscores its commitment to disciplined capital allocation and long-term value creation as it prioritizes investment in its development pipeline and commercial operations.
Under the revised pay structure, the Representative Executive Officer and President will see an 85% reduction in their performance-linked bonus, while Executive Officers will face a 70% cut. The reductions will apply from January through December 2026, signaling tighter alignment between executive compensation and company performance for shareholders and other stakeholders.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma reported a year of disciplined execution in 2025, strengthening its commercial base in Japan and APAC while advancing a maturing pipeline. The company’s aneurysmal subarachnoid haemorrhage drug PIVLAZ® consolidated its position as the standard of care in Japan, driving market share to 74% and 6.8% year-on-year net sales growth, while insomnia therapy QUVIVIQ™ delivered a more than threefold sales increase supported by expanded Asian manufacturing capacity to secure supply and improve margins.
Operationally, Nxera pushed several partnered assets forward, including Phase 3 initiation of Neurocrine’s NBI-‘568 muscarinic agonist and encouraging Phase 1 oncology data for HTL’732, generating around US$35 million in milestones and a further US$3.6 million from Centessa for OX2R agonist ORX142. The company undertook a focused restructuring to concentrate investment on high-potential platforms, regain full rights to its Phase 2–ready GPR52 schizophrenia program for potential partnering, launch a new proprietary obesity and metabolic disease pipeline and expand its late- and commercial-stage portfolio in Japan/APAC through licensing vamorolone for Duchenne Muscular Dystrophy and progressing daridorexant toward South Korean approval.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma has moved to cut performance-linked remuneration for its top executives following the release of its full-year 2025 financial results. The company said it aims to underscore disciplined capital stewardship and long-term value creation while prioritizing resource deployment toward its drug pipeline and commercial activities.
Under the decision, the performance-based bonus of the Representative Executive Officer and President will be reduced by 85%, while Executive Officers will see a 70% reduction. The measures will apply for the full 2026 calendar year, signaling management’s willingness to share the financial burden and align compensation more closely with current performance and strategic priorities.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma reported a modest 2.7% year‑on‑year increase in revenue to ¥29.6 billion for the year ended December 2025, driven by strong growth in sales of its commercialized products PIVLAZ and QUVIVIQ. PIVLAZ revenue rose 6.8% to ¥13.5 billion and QUVIVIQ surged 223.9% to ¥4.3 billion, partially offsetting a decline in milestone income despite a higher number of milestones achieved.
The company’s operating loss widened to ¥8.5 billion as higher research and development spending, particularly on clinical‑stage programs in obesity and metabolic diseases and the impact of yen depreciation, outweighed cost savings in selling, general and administrative expenses. Additional finance costs tied to amended bond terms and remeasurement of contingent consideration pushed loss before tax to ¥15.0 billion and net loss attributable to shareholders to ¥12.5 billion, underscoring the earnings pressure from Nxera’s investment‑led growth strategy.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma will book an extraordinary loss of JPY 24.3 billion on the shares of its consolidated subsidiary Nxera Pharma UK Limited, reflecting a significant decline in the recoverable amount under Japanese GAAP valuation rules. The company stressed that this impairment is confined to its non-consolidated accounts and will be eliminated at the consolidated level, meaning there is no impact on its consolidated results or underlying group performance.
The loss arises from differences between Japanese GAAP and IFRS in how investments in subsidiaries are valued, highlighting an accounting-driven adjustment rather than a change in operating fundamentals. For investors and other stakeholders, the announcement signals that headline non-consolidated figures will be distorted by this one-off charge, while consolidated financials and the group’s ongoing operations and strategic positioning in specialty pharmaceuticals remain unaffected.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma reported a modest 2.7% rise in FY2025 revenue to ¥29.6 billion but swung to a core operating loss of ¥352 million and a deeper operating loss of ¥8.5 billion, with net loss attributable to owners widening to ¥12.5 billion. Profitability metrics deteriorated, total assets declined, cash and cash equivalents fell to ¥20.4 billion amid heavier financing outflows, and the company continued its no-dividend policy.
Despite the FY2025 loss, Nxera issued an optimistic FY2026 outlook, forecasting revenue of ¥33.8–48.8 billion and a strong recovery in core operating profit to ¥7.8–22.8 billion, with operating profit potentially turning positive. This guidance signals management’s expectation of a rebound in underlying business performance, which, if achieved, would materially improve margins and could bolster investor confidence after a year of weaker earnings and balance sheet contraction.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma, a Tokyo-listed biopharma group specializing in specialty medicines and GPCR structure-based drug discovery, operates commercial and R&D hubs in Japan, the UK, Switzerland and South Korea. The company targets high-value markets in Japan and the wider APAC region, combining its NxWave platform with alliances to broaden its pipeline of innovative therapies.
Nxera will receive a US$1.8 million milestone payment from Centessa Pharmaceuticals after Centessa achieved an early development milestone with its investigational orexin receptor 2 agonist, ORX489, for neuropsychiatric disorders. The payment, to be booked as first-quarter 2026 revenue, underscores the financial and strategic value of Nxera’s research collaboration model and validates its role in enabling partner-led drug development.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma has licensed a G protein-coupled receptor-targeted program to a newly founded independent spin-out backed by a leading international life sciences investment firm, taking an equity stake in the new company. The structure gives Nxera potential milestone and royalty income while allowing the NewCo to lead development and capital raising.
Under the agreement, Nxera retains certain rights to develop and commercialize the asset in Japan and selected Asia-Pacific markets, preserving its regional growth strategy. The company is also considering participation in the NewCo’s planned Series A round, and is reviewing the transaction’s impact on its 2026 financial results, with further disclosures to follow if required.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma reported positive top-line results from a Phase 3 trial in South Korea of its insomnia drug daridorexant 50 mg, showing statistically significant improvements over placebo in subjective total sleep time, time to fall asleep and wake after sleep onset, with a safety profile comparable to placebo. With insomnia affecting an estimated 6.5–11 million adults in South Korea and current treatment needs remaining high, the data clear a key regulatory hurdle and position Nxera to file for marketing authorization in early 2026 and potentially launch in 2027, extending the global footprint of QUVIVIQ and strengthening the company’s competitive position in the rapidly evolving insomnia treatment market.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen720.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma will receive a US$3.6 million milestone payment from Centessa Pharmaceuticals after Centessa achieved an early development milestone for ORX142, an investigational, orally administered orexin receptor 2 agonist being developed for neurological and neurodegenerative disorders. The payment, to be recognized as revenue in the fourth quarter of fiscal 2025, underscores the financial and strategic value of Nxera’s research collaborations and provides additional non-dilutive funding that supports its pipeline-focused business model and reinforces its position as a key partner in innovative neuroscience drug development.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen720.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma has signed an exclusive licensing agreement with Switzerland’s Santhera Pharmaceuticals to develop, manufacture and commercialize vamorolone, marketed as AGAMREE for Duchenne muscular dystrophy (DMD), in Japan, South Korea, Australia and New Zealand. Vamorolone, already approved in the US, EU, UK and China, has shown a substantially improved safety profile over conventional corticosteroids, including fewer vertebral fractures, a lower incidence of cataracts and preserved normal growth, while maintaining comparable efficacy, positioning it as a potential replacement for current steroid therapies in DMD. Under the deal, Nxera will handle regulatory approvals, any required clinical trials, and commercialization in the licensed territories, leveraging prior development and manufacturing experience gained via its 2023 acquisition of Idorsia’s Japan and APAC business. Nxera will pay Santhera an upfront USD 40 million (USD 30 million in cash and USD 10 million as a strategic equity investment), plus up to USD 165 million in sales and regulatory milestones and tiered royalties starting in the low teens, underscoring the strategic importance of vamorolone in expanding Nxera’s late- and commercial-stage pipeline and strengthening its position as a key rare-disease player in the APAC DMD market.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen718.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma has completed a tender offer to repurchase ¥5 billion in principal amount of its euro-yen denominated convertible bonds due 2028, paying a total of approximately ¥4.84 billion excluding accrued interest, based on a slight discount to face value. Following the transaction, ¥27 billion in principal amount of the convertible bonds remains outstanding, indicating a targeted balance-sheet action that may modestly reduce future potential dilution for shareholders while maintaining significant outstanding convertible debt.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen718.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma will regain full rights to its GPR52 agonist program for schizophrenia, including Phase 2–ready lead candidate NXE0048149, after Boehringer Ingelheim chose not to exercise its exclusive licensing option. The decision triggers the return to Nxera of all data and intellectual property generated under the collaboration and leaves the company free to pursue new strategic options, including a formal out‑licensing process in 2026, without affecting its current-period consolidated financial results.
NXE0048149, designed using Nxera’s NxWave discovery platform, has shown a highly favorable safety profile in Phase 1 studies, dose-proportional pharmacokinetics and pharmacodynamic evidence of engaging brain circuitry relevant to schizophrenia, supporting once‑daily dosing and continued development. With GPR52 expression linked to positive, negative and cognitive symptom domains, Nxera believes the program could offer a first‑in‑class treatment that addresses shortcomings of existing therapies, and management views the return of full rights as a strategic opportunity to partner the asset with a major pharmaceutical or specialized neuroscience company.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen858.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma Co., Ltd. has successfully completed its buyback and consent solicitation for its existing Euro-yen denominated convertible bonds due 2028. The company received the necessary electronic consents to approve an extraordinary resolution, allowing it to execute a supplemental trust deed and cancel a planned meeting. The tender offer was conducted with a total purchase price of ¥4,837,500,000, leaving ¥27,000,000,000 in principal amount of the bonds outstanding.
The most recent analyst rating on (JP:4565) stock is a Buy with a Yen1400.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma Co. Ltd announced the receipt of dividends amounting to JPY 8,193 million from its subsidiary, Nxera Pharma UK Limited. The dividend income of JPY 2,793 million will be recorded as non-operating income in the company’s non-consolidated financial statements for the fiscal year ending December 31, 2025, with no impact on its consolidated financial results.
The most recent analyst rating on (JP:4565) stock is a Buy with a Yen1400.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma Co., Ltd. has announced a buyback and consent solicitation for its existing convertible bonds due in 2028. The company aims to amend the terms of these bonds to reduce near-term redemption risk and secure liquidity for strategic growth investments. By removing bondholders’ early redemption options and conducting a tender offer up to ¥5 billion, Nxera seeks to maintain lower funding costs and avoid dilutive effects on shareholders.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen767.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
Nxera Pharma has announced the introduction of a new Employee Stock Ownership Plan (J-ESOP) for its employees residing in Japan, replacing the existing Restricted Share Unit Plan. This strategic move aims to enhance employee motivation and engagement by aligning their interests with the company’s performance, providing tax benefits, and reducing the concentration of share sales, thereby potentially increasing the company’s corporate value and market performance.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen767.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.